MikroScore
Science-backed ingredient evidence
Weak Evidence Safety: Likely safe Study dose: 100 mg/day

Pterostilben

Also known as: Pterostilbene, 3,5-Dimethoxy-4'-hydroxystilben, Blaubeer-Stilben

Summary Weak Evidence

Pterostilbene is a resveratrol analogue from blueberries with superior bioavailability (~80% vs 20%). Similar mechanisms (SIRT1, AMPK) but fewer human studies to date.

EU Health Claims: No approved claims

No EFSA health claims authorized for pterostilbene. Available as a dietary supplement in the EU. No novel food classification required, as it occurs naturally in blueberries. Regulatory status similar to resveratrol.

AI Summary

Quick verdict

Pterostilbene is a resveratrol analogue from blueberries with superior bioavailability (~80% vs 20%). Similar mechanisms (SIRT1, AMPK) but fewer human studies to date.

What the evidence supports

Small RCTs show effects on blood pressure, cholesterol, and glucose. Bioavailability 4× superior to resveratrol.

What is NOT supported

Clinical human trials are absent or very weak. Long-term safety in humans is largely unexplored.

EU/EFSA status

Not approved. No EFSA health claims authorized for pterostilbene. Available as a dietary supplement in the EU. …

Safety

Likely safe

This AI summary is generated from the structured data on this page.

What is Pterostilbene?

Pterostilbene is a naturally occurring stilbenoid – chemically closely related to resveratrol but with two methyl groups instead of hydroxyl groups. This small structural modification creates a substantial difference in pharmacokinetics and bioavailability.

Pterostilbene occurs primarily in blueberries (especially Pterocarya fraxinifolia), grapes, and certain types of wood. However, dietary concentrations are too low for therapeutic effects, making supplementation the only practical approach to achieve clinically relevant doses.

Pterostilbene vs. Resveratrol: The Crucial Difference

PropertyResveratrolPterostilbene
Oral bioavailability~20%~80%
Half-life~14 min~105 min
LipophilicityLowHigh (better membrane penetration)
MetabolismRapid conjugationSlower degradation

The practical implication: same dose yields 4× higher plasma levels with 7× longer circulation time. Pterostilbene is essentially resveratrol with a bioavailability fix built in.

Mechanisms of Action (Similar to Resveratrol)

  • SIRT1 activation: NAD+-dependent deacetylase that promotes stress resistance, mitochondrial biogenesis, and DNA repair
  • AMPK: Master metabolic sensor that inhibits mTOR and stimulates autophagy
  • Nrf2 pathway: Antioxidant master regulator (similar mechanism to sulforaphane)
  • NF-κB inhibition: Dampens inflammatory signaling cascade

All of these pathways are well-documented in both cell culture and animal models. Whether they translate to meaningful human benefits remains the open question.

What Do the Human Studies Actually Show?

Demonstrated Effects (Small RCTs)

The evidence base for pterostilbene in humans is modest compared to resveratrol. However, small randomized controlled trials have shown:

  • Blood pressure: ~8 mmHg systolic reduction at 125 mg/day in a controlled trial
  • Glucose and lipids: Improvements in metabolic parameters observed in small studies with metabolic syndrome subjects
  • Inflammation markers: CRP and TNF-α reductions noted in some (but not all) trials

These effects are consistent with the proposed mechanisms, but sample sizes have been small (typically n=40–80).

The Critical Safety Signal: LDL Elevation

A significant and unexpected finding emerged in the Riche et al. (2013) RCT: at 250 mg/day, pterostilbene raised LDL cholesterol – but this effect did not occur at 125 mg. This is not a trivial finding. For someone with cardiovascular risk factors or existing dyslipidemia, this represents a genuine clinical trade-off. Higher doses may reduce blood pressure but at the cost of an unfavorable lipid shift.

What Remains Unproven

  • Superiority over resveratrol in clinical outcomes: There are no head-to-head human trials comparing pterostilbene directly to resveratrol in terms of cardiovascular or longevity outcomes
  • Lifespan effects in humans: All longevity data comes from animal models or cell culture
  • Optimal dosing: Whether 50 mg, 100 mg, or 150 mg is the “sweet spot” remains unclear
  • Long-term safety: Most human trials have been short-term (8–16 weeks)

Is Pterostilbene Safe?

At 50–125 mg/day, pterostilbene is considered likely safe based on available evidence. No serious adverse events have been reported in human studies. However, the LDL elevation at 250 mg serves as a reminder: more is not always better.

Key precautions:

  • Start at lower doses (50–100 mg/day) to assess individual response
  • If you have dyslipidemia or cardiovascular disease, monitor lipid panels after starting
  • Do not combine with anticoagulants (warfarin, direct oral anticoagulants) without medical supervision – stilbenoids may potentiate antiplatelet activity
  • Pregnant and nursing women should avoid (insufficient safety data)

Practical Takeaway

Pterostilbene’s superior bioavailability compared to resveratrol is genuine and well-documented. Whether this translates to greater clinical benefit remains an open question – the human evidence is too limited to claim superiority. It is a reasonable choice for someone interested in SIRT1 and AMPK activation, particularly if they tolerated resveratrol poorly or prefer a longer half-life. However, it is not a proven life-extension agent. Start conservatively (50–125 mg/day), monitor response, and reassess. The LDL signal at higher doses warrants respect.

Key Studies

Resveratrol and pterostilbene as a microRNA-mediated chemopreventive and therapeutic strategy in prostate cancer

Kumar et al. (2017)

Review: Pterostilbene exhibits ~80% oral bioavailability versus ~20% for resveratrol. Activates SIRT1, AMPK, and Nrf2. Longer half-life due to methyl groups rather than hydroxyl groups.

PubMed PMID 28662290

Pterostilbene as a Multifaceted Anticancer Agent: Molecular Mechanisms, Therapeutic Potential and Future Directions

Ali et al. (2025)

Pharmacokinetic study: Pterostilbene achieves 4-fold higher plasma levels than resveratrol at identical doses, with prolonged half-life and enhanced tissue distribution.

PubMed PMID 40411697
Editorial notice: For most ingredients described here, no health claims are approved in the EU (Regulation (EC) 1924/2006). Evidence levels are editorial assessments of research quality — not health promises. This content is not a substitute for medical advice and does not constitute a recommendation to treat, alleviate, or prevent any disease.